Abstract: Objective: To evaluate the prognosis and the effect of perioperative allogenenic blood transfusions on disease- free survival in non- small cell lung cancer patients treated with curative pulmonary resection. Methods: Of 280 patients, 145 (51.8%) received allogeneic blood products. Survival analysis included univariate log- rank test and multivariate Cox regression model. Results: Multivariate analysis showed that the factors influencing disease- free survival time were cellular differentiation, tumor stage and perioperative blood transfusion. Perioperative blood transfusion was an independent prognostic factor for disease- free survival. Conclusion: Perioperative allogeneic blood transfusion has an independent, adverse impact on survival in non- small cell lung cancer patients treated with curative pulmonary resection. Using perioperative allogeneic blood transfusions should be avoided in non- small cell lung cancer patients.